RENEW 2: Cagrilintide Phase 3 trial (NCT07220759)
Efficacy and Safety of Cagrilintide for Weight Management in Participants With Overweight or Obesity and Type 2 Diabetes
Registry record checked
At a glance
- Phase
- Phase 3
- Status
- Active, not recruiting
- Enrolment
- 330
- estimated
- Start
- 5 Nov 2025 (actual)
- Primary completion
- 12 May 2027 (estimated)
- Sponsor
- Novo Nordisk A/S
Design
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Cagrilintide | Experimental | Drug: Cagrilintide | Participants will receive cagrilintide subcutaneously once weekly for 64 weeks. |
| Placebo | Placebo comparator | Drug: Placebo (matched to Cagrilintide) | Participants will receive placebo matched to cagrilintide subcutaneously once weekly for 64 weeks. |
Endpoints
Primary endpoint
| Measure | Time frame |
|---|---|
| Relative change in body weight | From baseline (week 0) to end of treatment (week 64) |
Endpoints
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Number of participants with achievement of >= 10% body weight reduction (yes/no) | From baseline (week 0) to end of treatment (week 64) |
| Number of participants with achievement of >= 15% body weight reduction (yes/no) | From baseline (week 0) to end of treatment (week 64) |
| Change in waist circumference | From baseline (week 0) to end of treatment (week 64) |
| Ratio to baseline in lipids: triglycerides | From baseline (week 0) to end of treatment (week 64) |
| Ratio to baseline in high sensitivity C-reactive protein (hsCRP) | From baseline (week 0) to end of treatment (week 64) |
| Change in glycated haemoglobin (HbA1c) | From baseline (week 0) to end of treatment (week 64) |
| Change in impact of weight on quality of life-lite clinical trials version (IWQOL-Lite-CT) physical function score | From baseline (week 0) to end of treatment (week 64) |
| Change in systolic blood pressure (SBP) | From baseline (week 0) to end of treatment (week 64) |
| Change in body weight | From baseline (week 0) to end of treatment (week 64) |
| Number of participants with achievement of >= 5% body weight reduction (yes/no) | From baseline (week 0) to end of treatment (week 64) |
| Change in SF-36v2® health survey acute (SF-36v2® acute) physical component summary score | From baseline (week 0) to end of treatment (week 64) |
| Change in SF-36v2® mental component summary score | From baseline (week 0) to end of treatment (week 64) |
Eligibility
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- Not stated
Results
Results
No results posted on ClinicalTrials.gov as of 2 Oct 2026.
Sources
- 1Efficacy and Safety of Cagrilintide for Weight Management in Participants With Overweight or Obesity and Type 2 DiabetesClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
Found an error? Report a correction.